Literature DB >> 3805409

Clinical use of rapid T2 weighted partial saturation sequences in MR imaging.

G M Bydder, J A Payne, A G Collins, D G Thomas, C H Davis, I J Cox, B D Ross, I R Young.   

Abstract

Rapid T2 dependent field echo [partial saturation (PS)] sequences were used in 38 patients with brain tumors, intracerebral hematomas, and cerebral infarction as well as other neurological and abdominal disease. Reduction in the radiofrequency excitation angle (alpha) from 90 to 30 degrees produced an increase in lesion contrast as did change of echo time (TE) from 33 to 59 or 120 ms using repetition time (TR) values in the range of 120-500 ms. The PS sequence showing most lesion contrast was compared with conventional spin echo (SE 1,500/80 and SE 1,500/120) and inversion recovery (IR 1,500/500/44 and IR 1,500/100/44) sequences. Although PS sequences with TE = 39 ms were usually inferior to conventional SE sequences, those with TE = 59 or 120 ms were comparable and in some cases (particularly hematomas) superior. The PS sequences with alpha of approximately 30 degrees, TR of 80-250 ms, and TE of 60-120 ms offer considerable savings in time compared with conventional sequences although more work will be required to explore the limits of this approach and to optimize sequences at different field strengths.

Entities:  

Mesh:

Year:  1987        PMID: 3805409     DOI: 10.1097/00004728-198701000-00004

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  3 in total

1.  Clinical utility of partial flip angle T2-weighted spin-echo imaging of the brain.

Authors:  K H Chang; J G Yi; M H Han; M H Cho; M C Han; Z H Cho; C W Kim
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

Review 2.  Magnetic resonance in diseases of the nervous system.

Authors:  B E Kendall
Journal:  Arch Dis Child       Date:  1988-11       Impact factor: 3.791

Review 3.  Medical imaging.

Authors:  L Kreel
Journal:  Postgrad Med J       Date:  1991-04       Impact factor: 2.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.